NCT01019772已完成3 期
A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberix™ Vaccine in Healthy Infants at Two, Four and Six Months of Age
LG Life Sciences2 个研究点 分布在 1 个国家目标入组 217 人开始时间: 2007年7月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 217
- 试验地点
- 2
- 主要终点
- Proportion of subjects who have obtained protective antibody response with anti-PRP antibody titer not less than 1㎍/mL after the 3rd vaccination (at 4 weeks after the 3rd vaccination) in the test group and control group.
研究概览
简要总结
The purpose of this study is to evaluate and compare the immunogenicity and safety of LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) to that of Hiberix™ at vaccination in healthy infants at their 2, 4, and 6 months of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 49 Days 至 84 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female infants aged from 49 days to 84 days at the time of enrollment.
- •The gestation period was 37 weeks or longer, and birth weight was 2.5 kg or more.
- •The infants and their parents/legally acceptable representative could comply with all of the scheduled visits in the study and the study requirements related to protocol compliance.
- •The parents/legally acceptable representative (LAR) signed the written consent form.
排除标准
- •Had previously received Haemophilus influenzae type b vaccine prior to this clinical study.
- •Had a plan for vaccination with the vaccine other than those permitted in the protocol based on the standard vaccination schedule.
- •Had been contacted with a patient with confirmed Hib infection within 30 days before the study start.
- •Had had fever of ≥ 37.5°C within the last 3 days (If measured by tympanic thermometer, fever of 38°C or higher)
- •Had or were suspected for immune function disorders; had previously received or were suspected to receive the immunosuppressive therapy; or had received the immunosuppressive therapy within 30 days prior to participating in the study (including systemic corticosteroids or inhalation corticosteroids) (However, it was not the exclusion criteria to have received corticosteroid therapy (prednisolone equivalent ≤ 0.5 mg/kg/day) not more than for 14 consecutive days at least 30 days before their participation in the study).
- •Had received the treatment of parenteral immunoglobulin or blood products after birth.
- •Had allergic history to be considered due to any component of the vaccine including excipients or preservatives.
- •Three preceding generations in an ancestral line were not of Korean heritage.
- •Had or were suspected to have significant disorders of blood, heart, liver, kidney, nervous system, respiratory system, or digestive system, or the investigator decided that the evaluation of study objective might be interrupted.
- •Had been treated with other investigational drug by participating in another clinical trial within 30 days prior to this study entry, or were participating in another clinical study at that time.
- •Had plans to move away from the area of the study site before completing the study.
- •Inappropriate to take part in this clinical study in the principal investigator or sub-investigator's opinion, for the reasons other than above criteria.
结局指标
主要结局
Proportion of subjects who have obtained protective antibody response with anti-PRP antibody titer not less than 1㎍/mL after the 3rd vaccination (at 4 weeks after the 3rd vaccination) in the test group and control group.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).Hepatitis BNCT00697216GlaxoSmithKline340
已完成
2 期
Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 yHepatitis BNCT00698906GlaxoSmithKline160
已完成
4 期
A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy AdultsHepatitis BNCT02203357Peking University353
已完成
1 期
Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy AdultsInfluenza, AvianNCT03745274AVIR Green Hills Biotechnology AG36
已完成
3 期
MSB11022 in Moderate to Severe Rheumatoid ArthritisModerate to Severe Rheumatoid ArthritisNCT03052322Fresenius Kabi SwissBioSim GmbH288